Advocacy Actions
Meeting with Vice-Governor of Anhui Province on Healthcare Industry
European Chamber Pharmaceutical Working Group representatives met with Mr. Xie Guangxiang, Vice-Governor of Anhui Province on healthcare industry and healthcare reform.
Read moreComments on MEP's Administrative Regulations on Access to and Benefits Sharing on Biological Genetic Resources (Draft for Comments)
European Chamber Comments on MEP's Administrative Regulations on Access to and Benefits Sharing on Biological Genetic Resources (Draft for Comments)
Read moreWork-level Meeting with CCPIT and Six Ministries to Discuss Further Openness of Foreign Investment and Guofa No.5
With the release of the State Council’s Notice on Several Measures on Promoting Further Openness and Active Utilization of Foreign Investment (Guofa No.5), the China Council for The Promotion of International Trade (CCPIT) organized a work-level meeting together with the European Chamber to discuss its implementation and the concerns of European business in China.
Read moreComments on Anti-unfair Competition Law (Draft Revision)
The European Chamber submitted consolidated comments from member companies to the National People's Congress on Anti-unfair Competition Law (Draft Revision).
Read moreSpeech at the 2017 International Pharmaceutical Innovation Forum in Nanjing
European Chamber Secretary General Mr. Adam Dunnett gave a keynote speech at 2017 International Pharmaceutical Innovation Forum in Nanjing, raising European businesses' recommendations on promoting innovation in China
Read moreLobby Letter to Department of Market Order, MOFCOM, on Two-Invoice Policy
European Chamber Pharmaceutical Working Group issued a lobby letter to the Department of Market Order, MOFCOM, on suggestions on the Two-Invoice Policy.
Read moreLobby Letter to CFDA on Drug Renaming and Impact on Reimbursement
Lobby Letter to CFDA on Drug Renaming and Impact on Reimbursement
Read moreComments to the CFDA's Draft Regulation on "Advertisement for Pharmaceuticals, Medical Devices and Dietary Supplements"
The Healthcare Equipment Working Group submitted comments to the CFDA's draft regulation on "Advertisement for Pharmaceuticals, Medical Devices and Dietary Supplements"
Read moreComments to the CFDA's Draft Regulation on ”Administrative Measures on Safety Supervision Information Disclosure for Food and Pharmaceuticals ”
The Health Care Equipment (HCE) Working Group submitted comments to the CFDA's Draft Regulation on ”Administrative Measures on Safety Supervision Information Disclosure for Food and Pharmaceuticals ”
Read moreComments to the CFDA's Draft Regulation on ”Protection of Confidentiality during Evaluation, Examination & Approval of Pharmaceuticals and Medical Devices”
The Healthcare Equipment and Pharmaceutical Working Groups submitted comments to the CFDA's Draft Regulation on ”Protection of Confidentiality during Evaluation, Examination & Approval of Pharmaceuticals and Medical Devices”
Read more